April 27, 2017
Patients with type 2 diabetes experienced gastrointestinal events less frequently when treated with a once-weekly dose of the glucagon-like peptide-1 receptor agonist exenatide than a twice-daily dose of exenatide or liraglutide, according to findings published in Diabetes, Obesity and Metabolism.
“GLP-1 [receptor agonists] have been shown to reduce HbA1c and body weight, with low intrinsic risk of hypoglycemia,” the researchers wrote. “One potential [adverse event] associated with these agents is an increase in gastrointestinal events that is transient in most cases. As such, understanding the specific gastrointestinal [adverse event] profile and how it varies across the GLP-1 [receptor agonist] class is of interest for patients and physicians and may be useful in guiding therapy.”